NCT00003178 arm group 133800a8b6b6303f76c57972ca120b3b [clinicaltrials_resource:NCT00003178/arm-group/133800a8b6b6303f76c57972ca120b3b]
NCT00003178 arm group 133800a8b6b6303f76c57972ca120b3b [clinicaltrials_resource:NCT00003178/arm-group/133800a8b6b6303f76c57972ca120b3b]
Bio2RDF identifier
NCT00003178/arm-group/133800a8b6b6303f76c57972ca120b3b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 3800a8b6b6303f76c57972ca120b3b
description [clinicaltrials_vocabulary:description]
Patients receive idarubicin IV ...... otherapy to symptomatic sites.
identifier
clinicaltrials_resource:NCT00003178/arm-group/133800a8b6b6303f76c57972ca120b3b
title
NCT00003178 arm group 133800a8b6b6303f76c57972ca120b3b
@en
type
label
NCT00003178 arm group 133800a8 ...... 800a8b6b6303f76c57972ca120b3b]
@en